Clinical trials: Hereditary Hemorrhagic Telangiectasia, active
Hereditary Haemorrhagic Telangiectasia (HHT)
Quality of Life in Pediatric Participants With HHT
This observational study evaluates health-related quality of life (HR-QoL) in pediatric and young adult patients aged 2-25 years with Hereditary Hemorrhagic Telangiectasia (HHT).
- Trial name
- NCT07474428
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Ashley Nelson
Hereditary Hemorrhagic Telangiectasia (HHT), Obstructive Sleep Apnea (OSA)
Prevalence of Obstructive Sleep Apnea in HHT and HHT-specific Challenges in OSA-therapy - a Retrospective Cohort Study
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder (prevalence approx. 1:5,000-1:8,000) characterized by recurrent epistaxis, mucocutaneous telangiectasias and visceral vascular malformations.
- Trial name
- NCT07886632
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Essen
Hereditary Hemorrhagic Telangiectasia
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
The purpose of this study is to: evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers evaluate the efficacy, safety, tolerability and PD of…
- Trial name
- InsigHHT (NCT06659640)
- Testing
- ALN-6400
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Hereditary Hemorrhagic Telangiectasia (HHT)
Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)
The primary purpose of this study is to assess the safety and tolerability of TX002100 in participants with hereditary hemorrhagic telangiectasia (HHT).
- Trial name
- NCT07863609
- Testing
- TX002100
- Volunteers
- 20 people
- Sponsor
- Tectonic Operating Company, Inc.
Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
This is a 2-part study evaluating ATV-1601 in participants with moderate to severe HHT. Part 1 is a randomized, double-blind, placebo-controlled study evaluating 3 dosing regimens of ATV-1601.
- Trial name
- NCT07601425
- Testing
- ATV-1601
- Where
- 6 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Atavistik Bio, Inc
Vascular Anomaly, Osler Rendu Disease
Pregnancy in Women With Rare Multisystemic Vascular Diseases: COGRare5 Study
There are no prospective studies of pregnancies for the diseases studied here in (Heredity Hemorrhagic Telangiectasia, Marfan syndrome or related, primary lower limb lymphedema, superficial arteriovenous malformations, and…
- Conditions
- Vascular Anomaly, Osler Rendu Disease, Marfan Syndrome or Related, Lymphedema Primary
- Trial name
- COGRare5 (NCT04194619)
- Testing
- Questionnaire
- Where
- 37 sites in France
- Volunteers
- 400 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia
A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
The primary objective of this trial is to assess the efficacy of engasertib 40 mg once daily (QD) in reducing the frequency of epistaxis compared to placebo QD during 28 weeks of double-blind treatment in participants with…
- Trial name
- NCT07743671
- Testing
- Engasertib
- Where
- 4 sites in United States
- Volunteers
- 240 people
- Sponsor
- Vaderis Therapeutics AG
Hereditary Hemorrhagic Telangiectasia
Body Donation in HHT
The possibility of body donation in hereditary hemorrhagic telangiectasia (HHT) means that human tissue samples with and without vascular malformations can be analyzed. The aim is to gain insights into the disease mechanism.
- Trial name
- NCT07826845
- Testing
- body donation in HHT
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- University Hospital, Essen
Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
This is a Phase 1/2, randomized, double-blind, placebo-controlled, first-in-human study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneously administered DIAG723 in adult patients with…
- Trial name
- DIAMOND (NCT07623525)
- Testing
- DIAG723
- Where
- 11 sites in Australia, Canada and 1 more
- Volunteers
- 93 people
- Sponsor
- Diagonal Therapeutics, Inc.
Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
Topical TOR-582 Treatment of Epistaxis in HHT
People with hereditary hemorrhagic telangiectasia (HHT) often experience frequent and severe nosebleeds that can disrupt daily life and lead to anemia, medical procedures, and reduced quality of life.
- Trial name
- NCT07667413
- Testing
- Topical sirolimus ointment
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Columbia University
Haemorrhagic Hereditary Telangiectasia
Institutional Registry of Haemorrhagic Hereditary Telangiectasia
The purpose of this study is to create an institutional and population-based registry of Haemorrhagic Hereditary Telangiectasia with a prospective survey based on epidemiological data, risk factors, diagnosis, prognosis…
- Trial name
- NCT01761981
- Where
- Argentina
- Volunteers
- 590 people
- Sponsor
- Hospital Italiano de Buenos Aires
Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT).
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis
- Trial name
- CHORUS (NCT06259292)
- Where
- 16 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Cure HHT
Hereditary Hemorrhagic Telangiectasia, Rendu Osler Disease
Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia
The goal of this clinical trial is to evaluate in real life, in patients with Hereditary Hemorrhagic Telangiectasia (HHT), the tolerance of the strategy of use of anticoagulant and/or antiplatelet, by comparing a new exposure…
- Trial name
- PROPLACO-Tel (NCT05641142)
- Testing
- monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease
- Where
- 18 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Hereditary Hemorrhagic Telangiectasia
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
This research study is studying to see whether bevacizumab may treat chronic bleeding and iron deficiency anemia in Hereditary Hemorrhagic Telangiectasia (HHT).
- Trial name
- TrUST-HHT (NCT04404881)
- Testing
- Bevacizumab (Avastin®)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Hanny Al-Samkari, MD
Hereditary Hemorrhagic Telangiectasia, HHT
CHORUS - Comprehensive HHT Outcomes Registry of the United States (Formerly OUR HHT Registry)
The goal of this study is to better understand HHT, the symptoms and complications it causes ("outcomes") and how the disease impacts people's lives.
- Conditions
- Hereditary Hemorrhagic Telangiectasia, HHT, Arteriovenous Malformation of Brain
- Trial name
- NCT04150822
- Testing
- Registry and Saliva sample
- Where
- Canada
- Volunteers
- 296 people
- Sponsor
- Unity Health Toronto
Hereditary Hemorrhagic Telangiectasia, Epistaxis
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
During the Efficacy Study (Part B), the investigators will study whether Pazopanib, taken daily for 24 weeks, will reduce the severity of nose bleeds in patients with hereditary hemorrhagic telangiectasia (HHT).
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia, Nosebleed
- Trial name
- Paz (NCT03850964)
- Testing
- Pazopanib
- Where
- 11 sites in United States
- Volunteers
- 70 people
- Sponsor
- Cure HHT
Hereditary Hemorrhagic Telangiectasia (HHT)
Assess Safety and Efficacy of VAD044 in HHT Patients
Part I: The purpose of this Phase 1b proof of concept study, randomised, placebo controlled, double blind, multicentre study is to asssess safety and efficacy of 2 doses of VAD044 in adult HHT patients.
- Trial name
- NCT05406362
- Testing
- VAD044 Part I, VAD044 Part II
- Where
- 7 sites in United States, Belgium and 4 more
- Volunteers
- 75 people
- Sponsor
- Vaderis Therapeutics AG
Telangiectasia, Hereditary Hemorrhagic
Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients
Patients affected by hereditary hemorrhagic telangiectasia (HHT) very often suffer from recurrent nosebleeds called epistaxis. There is no treatment currently available to reduce the frequency or severity of epistaxis.
- Trial name
- EPISTOP (NCT04976036)
- Testing
- Nintedanib
- Where
- 3 sites in France, Switzerland
- Volunteers
- 48 people
- Sponsor
- Dr. Romain Lazor
Hereditary Hemorrhagic Telangiectasia (HHT), Pulmonary Hypertension
Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network
High cardiac output secondary to hepatic arteriovenous malformations may be isolated or associated with left heart failure with post-capillary pulmonary hypertension.
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT), Pulmonary Hypertension, Bevacizumab
- Trial name
- BevaHHearT (NCT07445347)
- Testing
- Bevacizumab
- Where
- France
- Volunteers
- 111 people
- Sponsor
- Poitiers University Hospital
Hereditary Haemorrhagic Telangiectasia, PFO - Patent Foramen Ovale
Non-Invasive Detection of Pulmonary Right-to-Left Shunts Using the SONAS Ultrasound Device
The goal of this clinical trial is to learn how well the SONAS ultrasound device can detect right-to-left shunts of adults with hereditary hemorrhagic telangiectasia (HHT) who are already scheduled for a contrast bubble…
- Conditions
- Hereditary Haemorrhagic Telangiectasia, PFO - Patent Foramen Ovale, Pulmonary Arteriovenous Malformation
- Trial name
- SONAS (NCT07414446)
- Testing
- Transcranial Ultrasound Device
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- St. Antonius Hospital